Literature DB >> 10559558

Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation.

A Mustafa1, L Lannfelt, L Lilius, A Islam, B Winblad, A Adem.   

Abstract

The plasma insulin-like growth factor I (IGF-I) level was determined in family members carrying the Swedish amyloid precursor protein (APP) 670/671 mutation with or without Alzheimer's disease (AD) and in age-matched controls from the same family. Plasma growth hormone (GH) and prolactin (PRL) levels were also determined. Measurement of the plasma IGF-I level by radioimmunoassay revealed a significant reduction only in the family members with AD compared to age-matched controls. However, there was no significant difference in the levels of GH and PRL between the mutation carriers with or without AD and their respective age-matched controls. These findings indicate that the mechanism(s) regulating GH and PRL were preserved and those regulating IGF-I levels might be affected in AD patients with the Swedish APP 670/671 mutation. CopyrightCopyright 1999S.KargerAG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559558     DOI: 10.1159/000017188

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  22 in total

Review 1.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

2.  Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.

Authors:  Maria Clara Selles; Juliana T S Fortuna; Maria F Zappa-Villar; Yasmin P R de Faria; Amanda S Souza; Claudia K Suemoto; Renata E P Leite; Roberta D Rodriguez; Lea T Grinberg; Paula C Reggiani; Sergio T Ferreira
Journal:  Mol Neurobiol       Date:  2019-11-23       Impact factor: 5.590

3.  T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide.

Authors:  Tatsuo Kimura; Phuong Thi Hong Nguyen; Son Anh Ho; Anh Hai Tran; Taketoshi Ono; Hisao Nishijo
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

5.  Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner.

Authors:  T Niikura; Y Hashimoto; T Okamoto; Y Abe; T Yasukawa; M Kawasumi; T Hiraki; Y Kita; K Terashita; K Kouyama; I Nishimoto
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 6.  Dementia: a neuroendocrine perspective.

Authors:  A Polleri; M V Gianelli; G Murialdo
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

7.  Amyloid-β transmission or unexamined bias?

Authors:  Hieab H H Adams; Sonja A Swanson; Albert Hofman; M Arfan Ikram
Journal:  Nature       Date:  2016-09-15       Impact factor: 49.962

8.  Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels.

Authors:  Marta Bolós; Silvia Fernandez; Ignacio Torres-Aleman
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

9.  The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice.

Authors:  Kendra L Puig; Joshua A Kulas; Whitney Franklin; Sharlene G Rakoczy; Giulio Taglialatela; Holly M Brown-Borg; Colin K Combs
Journal:  Neurobiol Aging       Date:  2016-01-06       Impact factor: 4.673

Review 10.  Brain repair and neuroprotection by serum insulin-like growth factor I.

Authors:  Eva Carro; Jose Luis Trejo; Angel Núñez; Ignacio Torres-Aleman
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.